<p>软银集团在最近向美国证券交易委员会提交的文件中表示，在第四季度将其在 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免费报告）中的持仓减少了 13.3%。该机构投资者在此期间出售了 1,005,726 股后，持有 6,541,190 股该公司的股票。Neumora Therapeutics 占软银集团投资组合的 0.3%，使其成为该公司第 12 大持仓。软银集团在最近的报告期末持有约 4.05% 的 Neumora Therapeutics，价值 69,337,000 美元。</p>
<p>获取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
<p>其他几家对冲基金最近也对该公司的持仓进行了调整。资本国际投资者在第四季度将其在 Neumora Therapeutics 的股份增加了 692.1%。资本国际投资者现在持有 3,700,359 股该公司的股票，价值 39,224,000 美元，此前在上个季度又购买了 3,233,179 股。Schonfeld 战略顾问公司在第四季度将其在 Neumora Therapeutics 的持仓增加了 273.9%。Schonfeld 战略顾问公司现在持有 521,013 股该公司的股票，价值 5,523,000 美元，此前在上个季度又购买了 381,676 股。先锋集团在第四季度将其在 Neumora Therapeutics 的股份增加了 4.5%。先锋集团现在持有 4,572,308 股该公司的股票，价值 48,466,000 美元，此前在此期间又收购了 195,142 股。Cutter 资本管理公司在第四季度以 1,590,000 美元的估值购买了 Neumora Therapeutics 的新股份。最后，Rock Springs 资本管理公司在第四季度将其在 Neumora Therapeutics 的持仓增加了 15.3%。Rock Springs 资本管理公司现在持有 955,106 股该公司的股票，价值 10,124,000 美元，此前在上个季度又购买了 127,005 股。47.65% 的股票由机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>几位研究分析师对 NMRA 股票发表了看法。Guggenheim 在 3 月 7 日的报告中将 Neumora Therapeutics 的股票评级从 “买入” 下调至 “中性”。加拿大皇家银行在 3 月 4 日的报告中重申了 “行业表现” 评级，并对 Neumora Therapeutics 的股票设定了 4.00 美元的目标价。Needham &amp; Company LLC 在周二重申了 “买入” 评级，并对 Neumora Therapeutics 的股票设定了 5.00 美元的目标价。HC Wainwright 在 3 月 4 日的研究报告中将 Neumora Therapeutics 的目标价从 30.00 美元下调至 18.00 美元，并对该公司设定了 “买入” 评级。最后，William Blair 在 3 月 10 日的研究报告中将 Neumora Therapeutics 的股票评级从 “跑赢大盘” 下调至 “市场表现”。一位投资分析师对该股票给予了卖出评级，五位给予了持有评级，三位给予了买入评级。根据 MarketBeat 的数据，Neumora Therapeutics 目前的共识评级为 “持有”，平均目标价为 9.29 美元。</p>
<p><strong>查看我们对 Neumora Therapeutics 的最新分析</strong></p>
<h2>Neumora Therapeutics 股价上涨 8.2%</h2>
<p>Neumora Therapeutics 的股票在周五开盘价为 0.67 美元。该股票的 50 日移动平均价格为 0.86 美元，200 日移动平均价格为 4.42 美元。Neumora Therapeutics, Inc.的 12 个月低点为 0.61 美元，12 个月高点为 17.19 美元。该公司的市值为 1.0769 亿美元，市盈率为-0.36，贝塔值为 2.96。</p>
<p>Neumora Therapeutics（NASDAQ:NMRA - 获取免费报告）最近于 5 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.42 美元，低于市场共识预期的-0.40 美元，差距为-0.02 美元。整体来看，分析师预测 Neumora Therapeutics, Inc.在当前财年将发布-1.61 的每股收益。</p>
<h2>Neumora Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Neumora Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发针对脑疾病、神经精神疾病和神经退行性疾病的治疗方案。该公司开发的 navacaprant（NMRA-140）是一种新型的每日一次口服的κ-阿片受体拮抗剂，目前正在进行针对重度抑郁症的第三阶段临床试验。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而非 Neumora Therapeutics</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>分析师和机构继续大举押注 Alphabet</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>沃尔玛股票提醒：预计近期将有大幅价格波动</li>
</ul>
<p><strong>想看看其他对冲基金持有的 NMRA 股票吗？</strong> 访问 HoldingsChannel.com，获取 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Neumora Therapeutics 吗？</h2>
<p>在考虑 Neumora Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Neumora Therapeutics 并不在名单上。</p>
<p>虽然 Neumora Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

NMRA

<p>软银集团在 2023 年第四季度减少了对 Neumora Therapeutics, Inc.（纳斯达克代码：NMRA）13.3% 的持股，目前持有 6,541,190 股，价值 6934 万美元。这使得 Neumora 占其投资组合的 0.3%。其他对冲基金也调整了他们的持仓，国际资本投资者的持股增加了 692.1%。分析师对 NMRA 的评级不一，普遍评级为 “持有”，平均目标价为 9.29 美元。Neumora 的股票目前交易价格为 0.67 美元，较 12 个月高点 17.19 美元下跌</p>

<p>Softbank Group CORP. decreased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 6,541,190 shares of the company's stock after selling 1,005,726 shares during the period. Neumora Therapeutics comprises 0.3% of Softbank Group CORP.'s portfolio, making the stock its 12th biggest position. Softbank Group CORP. owned about 4.05% of Neumora Therapeutics worth $69,337,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>软银集团在最近向美国证券交易委员会提交的文件中表示，在第四季度将其在 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免费报告）中的持仓减少了 13.3%。该机构投资者在此期间出售了 1,005,726 股后，持有 6,541,190 股该公司的股票。Neumora Therapeutics 占软银集团投资组合的 0.3%，使其成为该公司第 12 大持仓。软银集团在最近的报告期末持有约 4.05% 的 Neumora Therapeutics，价值 69,337,000 美元。</p>
</div><p>Get <strong>Neumora Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
</div><p>Several other hedge funds also recently made changes to their positions in the business. Capital International Investors raised its stake in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Neumora Therapeutics by 273.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock valued at $5,523,000 after buying an additional 381,676 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Neumora Therapeutics by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company's stock worth $48,466,000 after acquiring an additional 195,142 shares during the period. Cutter Capital Management LP bought a new stake in Neumora Therapeutics in the 4th quarter valued at $1,590,000. Finally, Rock Springs Capital Management LP increased its holdings in shares of Neumora Therapeutics by 15.3% in the fourth quarter. Rock Springs Capital Management LP now owns 955,106 shares of the company's stock valued at $10,124,000 after purchasing an additional 127,005 shares during the last quarter. 47.65% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也对该公司的持仓进行了调整。资本国际投资者在第四季度将其在 Neumora Therapeutics 的股份增加了 692.1%。资本国际投资者现在持有 3,700,359 股该公司的股票，价值 39,224,000 美元，此前在上个季度又购买了 3,233,179 股。Schonfeld 战略顾问公司在第四季度将其在 Neumora Therapeutics 的持仓增加了 273.9%。Schonfeld 战略顾问公司现在持有 521,013 股该公司的股票，价值 5,523,000 美元，此前在上个季度又购买了 381,676 股。先锋集团在第四季度将其在 Neumora Therapeutics 的股份增加了 4.5%。先锋集团现在持有 4,572,308 股该公司的股票，价值 48,466,000 美元，此前在此期间又收购了 195,142 股。Cutter 资本管理公司在第四季度以 1,590,000 美元的估值购买了 Neumora Therapeutics 的新股份。最后，Rock Springs 资本管理公司在第四季度将其在 Neumora Therapeutics 的持仓增加了 15.3%。Rock Springs 资本管理公司现在持有 955,106 股该公司的股票，价值 10,124,000 美元，此前在上个季度又购买了 127,005 股。47.65% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several research analysts have weighed in on NMRA shares. Guggenheim cut shares of Neumora Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, March 7th. Royal Bank of Canada reissued a &#34;sector perform&#34; rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, March 4th. Finally, William Blair cut shares of Neumora Therapeutics from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Neumora Therapeutics currently has a consensus rating of &#34;Hold&#34; and an average price target of $9.29.</p>
<div class="lb-trans"><p>几位研究分析师对 NMRA 股票发表了看法。Guggenheim 在 3 月 7 日的报告中将 Neumora Therapeutics 的股票评级从 “买入” 下调至 “中性”。加拿大皇家银行在 3 月 4 日的报告中重申了 “行业表现” 评级，并对 Neumora Therapeutics 的股票设定了 4.00 美元的目标价。Needham &amp; Company LLC 在周二重申了 “买入” 评级，并对 Neumora Therapeutics 的股票设定了 5.00 美元的目标价。HC Wainwright 在 3 月 4 日的研究报告中将 Neumora Therapeutics 的目标价从 30.00 美元下调至 18.00 美元，并对该公司设定了 “买入” 评级。最后，William Blair 在 3 月 10 日的研究报告中将 Neumora Therapeutics 的股票评级从 “跑赢大盘” 下调至 “市场表现”。一位投资分析师对该股票给予了卖出评级，五位给予了持有评级，三位给予了买入评级。根据 MarketBeat 的数据，Neumora Therapeutics 目前的共识评级为 “持有”，平均目标价为 9.29 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Neumora Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Neumora Therapeutics 的最新分析</strong></p>
</div><h2>Neumora Therapeutics Trading Up 8.2%</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 股价上涨 8.2%</h2>
</div><p>Neumora Therapeutics stock opened at $0.67 on Friday. The stock has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $4.42. Neumora Therapeutics, Inc. has a 12 month low of $0.61 and a 12 month high of $17.19. The company has a market capitalization of $107.69 million, a PE ratio of -0.36 and a beta of 2.96.</p>
<div class="lb-trans"><p>Neumora Therapeutics 的股票在周五开盘价为 0.67 美元。该股票的 50 日移动平均价格为 0.86 美元，200 日移动平均价格为 4.42 美元。Neumora Therapeutics, Inc.的 12 个月低点为 0.61 美元，12 个月高点为 17.19 美元。该公司的市值为 1.0769 亿美元，市盈率为-0.36，贝塔值为 2.96。</p>
</div><p>Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). As a group, analysts predict that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Neumora Therapeutics（NASDAQ:NMRA - 获取免费报告）最近于 5 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.42 美元，低于市场共识预期的-0.40 美元，差距为-0.02 美元。整体来看，分析师预测 Neumora Therapeutics, Inc.在当前财年将发布-1.61 的每股收益。</p>
</div><h2>Neumora Therapeutics Profile</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.</p>
<div class="lb-trans"><p>Neumora Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发针对脑疾病、神经精神疾病和神经退行性疾病的治疗方案。该公司开发的 navacaprant（NMRA-140）是一种新型的每日一次口服的κ-阿片受体拮抗剂，目前正在进行针对重度抑郁症的第三阶段临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Neumora Therapeutics</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Analysts and Institutions Continue to Bet Big on Alphabet</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Walmart Stock Alert: Big Price Move Expected Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Neumora Therapeutics</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>CRSPR 股票可能准备兑现其巨大的承诺</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>分析师和机构继续大举押注 Alphabet</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>沃尔玛股票提醒：预计近期将有大幅价格波动</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NMRA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 NMRA 股票吗？</strong> 访问 HoldingsChannel.com，获取 Neumora Therapeutics, Inc.（NASDAQ:NMRA - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NMRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neumora Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Neumora Therapeutics 吗？</h2>
</div><p>Before you consider Neumora Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Neumora Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Neumora Therapeutics 并不在名单上。</p>
</div><p>While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Neumora Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

软银集团公司在 Neumora Therapeutics, Inc.（NASDAQ:NMRA）持有价值 6934 万美元的头寸